Case report

Fatal bronchiolitis obliterans associated with chrysotherapy

LINN HOLNESS, JERRY TENENBAUM, NOEL B. E. COOTER, AND RONALD F. GROSSMAN

From the Departments of Medicine and Pathology, Mount Sinai Hospital and the University of Toronto

SUMMARY We describe a patient who developed fatal bronchiolitis obliterans following gold therapy and review the relationship between rheumatoid arthritis and bronchiolitis.

Various pulmonary complications of rheumatoid arthritis have been described. They include interstitial fibrosis, necrobiotic nodules, pleural effusions, Caplan's syndrome, and pulmonary vascular disease. Moreover, studies of pulmonary function in rheumatoid arthritis patients have included accounts of airways obstruction, and rarely, bronchiolitis obliterans has been described. Pulmonary reactions are also associated with gold salts and penicillamine, which are used to treat rheumatoid arthritis. Gold therapy is thought to cause interstitial pneumonitis and penicillamine has been linked with bronchiolitis obliterans. This report describes a patient with rheumatoid arthritis who developed fatal bronchiolitis obliterans after gold therapy.

Case report

A 65-year-old woman was admitted to hospital in April 1981 with increasing dyspnoea. In 1975 she developed polyarthritis, principally involving her hands, and was treated for 5 years with acetylsalicylic acid and a variety of nonsteroidal anti-inflammatory drugs including fenoprofen, ketoprofen, naproxen, and ibuprofen. In June 1980 her arthritic symptoms intensified, with increasing swelling and longer morning stiffness. The rheumatoid factor was positive to a dilution of 1:1280 and the ESR was 49 mm/hour (Westergren). Acetylsalicylic acid and naproxen were continued and gold treatment was begun. She received 25 mg of sodium aurothiomalate (Myocrisin) and then 50 mg every week for 15 weeks followed by 50 mg every 2 weeks.

Her past history included phlebitis 27 years previously, hypothyroidism, angina, atrial fibrillation, and temporal lobe epilepsy. Treatment, in addition to anti-inflammatory agents, included thyroxine, digoxin, frusemide, spironolactone, and primidone, all of which she had been taking for at least 3 years. She was a nonsmoker. She was a school teacher and she had no relevant occupational exposures.

In the autumn of 1980 mild exertional dyspnoea was noted. It increased gradually until February 1981, when wheezing was detected. At this time the gold injections were discontinued. A total dose of 1125 mg had been administered. No side effects were noted during the treatment. Her white blood cell count remained around $4 \times 10^9/l$, which it had been prior to the gold, and her ESR had decreased to 11.

Treatment with salbutamol and theophylline was begun, with slight improvement in symptoms initially. By mid-March the dyspnoea began to increase again, and cough productive of small amounts of white sputum began. The dyspnoea rapidly progressed, resulting in severe limitation. By the beginning of April she was bedridden. Other complaints were weakness and a weight loss of 15 lb (6.8 kg).

On admission the heart rate was 100; blood pressure was 150/90 mmHg with 15 mm of pulsus paradoxus and a respiratory rate of 38. The thyroid was palpable. There was diffuse wheezing on auscultation, and the breath sounds were markedly decreased. The cardiovascular and abdominal systems were normal. Initial laboratory investigations revealed a haemoglobin of 16.2 g/dl, leucocytes $10.1 \times 10^9/l$, with 90% polymorphs and 5% bands, ESR 3 mm/h, electrolytes normal, blood urea nitrogen 5.7 mmol/l (normal 3–6.5 mmol/l), creatinine 132.6 $\mu$mol/l (normal 50–110 $\mu$mol/l), rheumatoid factor positive 1:160. The chest x-ray showed hyperinflation, and no parenchymal infiltrates were seen...
air included pH 7.41, Pco₂ 5.9 kPa (normal 4.4-5.9 kPa), Po₂ 7.2 kPa (normal 10-14 kPa), Tco₂ 27 mmol/l, and on 35% oxygen pH 7.46, Pco₂ 4.8 kPa, Po₂ 13.8 kPa, Tco₂ 25 mmol/l. Because of concern about pulmonary emboli (dyspnoea, hypoxaemia, history of venous disease) a pulmonary angiogram was performed and was normal.

Initial treatment consisted of oxygen, intravenous hydrocortisone sodium succinate, and amiphylline, and salbutamol by inhalation. In spite of this vigorous bronchodilator therapy profound dyspnoea persisted, and there was no improvement in pulmonary function results (Table 1).

On 1 May 1981 her dyspnoea increased, and blood gases on 35% oxygen were pH 7.25, Pco₂ 8.6 kPa, Po₂ 11.7 kPa, Tco₂ 28 mmol/l. Later in the day she had a respiratory arrest and resuscitation efforts were unsuccessful.

Autopsy revealed bilateral widespread bronchiolitis, mild bilateral bronchopneumonia, bilateral mild nephrosclerosis, end-stage thyroiditis, atherosclerosis, and cholelithiasis. Examination of the lungs revealed mucous plugging of bronchioles and focal ulceration of the respiratory mucosa. Association with the plugs was a bronchiolitis characterised by peribronchiolar infiltration by lymphocytes and histiocytes. There were occasional collections of histiocytes within the airways. Some of the mucous plugs also showed an admixture of acute inflammatory cells. In addition there were scattered foci of bronchopneumonia associated with the areas of mucous plugging. A representative section is shown in Figs 2A, B.

**Discussion**

This patient had seropositive rheumatoid arthritis with no apparent lung involvement prior to gold therapy. After gold injections her joint symptoms improved, but progressive airway obstruction developed. Death resulted from widespread obliterative bronchiolitis. She had no known exposure to toxins usually associated with bronchiolitis obliterans, nor had she had a symptomatic viral infection. Since her rheumatoid disease was well controlled with gold therapy, it seems unlikely that the progressive bronchiolitis obliterans was simply an extra-articular manifestation of her rheumatoid disease. Her respiratory symptoms began only after the initiation of chrysotherapy, implicating gold at least temporally as an aetiological agent.

Bronchiolitis obliterans has been linked to both rheumatoid arthritis and therapy with penicillamine. It has been described in patients with rheumatoid disease who have received neither gold nor penicil-
Fatal bronchiolitis obliterans associated with chrysotherapy

Table 1  Pulmonary function results

<table>
<thead>
<tr>
<th></th>
<th>Predicted</th>
<th>16 April 1981</th>
<th>27 April 1981</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Observed</td>
<td>% Predicted</td>
<td>Observed</td>
</tr>
<tr>
<td>Total lung capacity (l)</td>
<td>4·1</td>
<td>—</td>
<td>7·3</td>
</tr>
<tr>
<td>Vital capacity (l)</td>
<td>2·4</td>
<td>1·3</td>
<td>1·4</td>
</tr>
<tr>
<td>Residual vol. (l)</td>
<td>1·6</td>
<td>—</td>
<td>5·9</td>
</tr>
<tr>
<td>Forced expired vol. in 1 s (l)</td>
<td>1·8</td>
<td>0·5</td>
<td>0·5</td>
</tr>
<tr>
<td>Flow rate at 50% forced VC (l/s)</td>
<td>2·4</td>
<td>0·3</td>
<td>0·2</td>
</tr>
<tr>
<td>Flow rate at 25% forced VC (l/s)</td>
<td>1·2</td>
<td>0·2</td>
<td>0·2</td>
</tr>
<tr>
<td>Airway resistance (RAW) cmH₂O/l/s</td>
<td>0·5</td>
<td>—</td>
<td>6·2</td>
</tr>
<tr>
<td>Lung diffusion (ml/min/mmHg)</td>
<td>20·6</td>
<td>—</td>
<td>13·2</td>
</tr>
</tbody>
</table>

Fig. 2A  Pulmonary bronchiole. Note the mucus plugging, focal ulceration of the respiratory mucosa, and peribronchial inflammation. The surrounding lung parenchyma is normal. (×47).

Fig. 2B  Same bronchiole. Note the mucosal disruption and peribronchial infiltration by lymphocytes and histiocytes. (×116).
lamine, in rheumatoid patients treated with penicillamine (one case in a woman treated with gold approximately 8 years prior to penicillamine therapy), and in one patient with cystinuria treated with penicillamine. Unlike the interstitial lung disease associated with gold therapy the outcome in patients with bronchiolitis is not favourable. However, a trial of corticosteroid therapy with careful monitoring of pulmonary function has been suggested. Most either succumb to the disease or are left with respiratory impairment. It has been suggested that the mechanism of injury involves both the underlying disease and treatment. Patients with connective tissue disease may be more prone to bronchiolitis, and the penicillamine may interfere with or alter the healing process. It is impossible to know if our patient's bronchiolitis obliterans was related solely to her rheumatoid disease or to gold therapy. It may be that both were necessary, with the gold salts acting to precipitate the disease process. Further investigation is required to separate the relationship between rheumatoid disease, the drugs given to treat it, and bronchiolitis obliterans. In the meantime it seems prudent to monitor patients on gold or penicillamine therapy for rheumatoid arthritis and to stop the drugs if any evidence of lung disease develops.

References